4.5. Interactions with other medicinal products or other forms of interactions

Experimental studies with PERMIXON do not show any negative interference with the therapeutic groups commonly associated with this condition (antibiotics for urinary tract infections, antiseptics and anti-inflammatory medicines).

Results from dedicated in vitro studies demonstrated the absence of inhibition and induction potential of lipidosterolic extract of Serenoa repens.

No pharmacokinetic interactions are expected with co-administered treatments.

4.6. Pregnancy and lactation

Not relevant, as this medicinal product is not indicated in women.

4.7. Effects on ability to drive and use machines

PERMIXON has no influence on the ability to drive and use machines.

4.8. Undesirable effects

The following table shows the undesirable effects observed in seven clinical studies with a total of 3593 patients:

2127 taking PERMIXON, for which the assessment of causality was not “excluded”.

The undesirable effects classified by organs or systems (according to MedDRA) are listed below as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000) and frequency unknown (it cannot be estimated on the basis of the data available).

No adverse drug reactions were “very rare”, “rare” or “very common” in frequency and therefore these columns were not presented in the table.

<table>
<thead>
<tr>
<th>Common (≥1/100 to &lt;1/10)</th>
<th>Uncommon (≥1/1000 to &lt;1/100),</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous system disorders</td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Nausea</td>
</tr>
</tbody>
</table>
explain the anti-inflammatory activity found both in animal models and benign prostatic hypertrophy.

Antiandrogenic properties are mainly due to an inhibition of the 5 alpha reductases responsible for transforming testosterone into its active metabolite dihydrotestosterone (DHT). This antiandrogenic activity is also increased by a reduction of the prolactin-dependent penetration of testosterone into the cell, an inhibition of oestrogen-dependent androgen receptor formation and finally an inhibition of DHT binding to its receptors.

This activity has been confirmed in an experimental rat model of benign prostatic hypertrophy.

Antiproliferative properties are explained by the fact that the lipidosterolic extract of Serenoa repens slows the proliferation of the glandular epithelium (estimated using the tritium-labelled thymidine index) induced by growth factors in human prostate organotypic cells.

It reduces protein synthesis in prostate cell cultures, stimulated by a combination of testosterone and prolactin, the latter of which regulates prostatic volume.

5.2. Pharmacokinetic properties

It is impossible to fully evaluate the pharmacokinetic profile of medicines of this type as it is impossible to determine the levels of all plant extract's components in the blood and, additionally, as some of these components already exist in the blood.

5.3. Preclinical safety studies

Non-clinical data reveal no special hazard for humans based on nonclinical studies of single and repeated dose toxicity, genotoxicity, and toxicity to reproduction.

No study was performed to assess the safety pharmacology and the carcinogenic potential.

6. PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Capsule content:
Macrogol 10 000

Body and cap of the capsule:
Gelatin, yellow iron oxide E 172, indigotin E 132, titanium dioxide E 171

6.2. Incompatibilities

Not applicable.
6.3. Shelf-life
3 years in blister pack (PVC-Aluminium)

6.4. Special precautions for storage
Do not store above 25°C.

6.5. Nature and content of container
Packs of 30 or 60 hard capsules, in PVC/Aluminium blister. Not all pack sizes may be registered.

6.6. Instructions for use/handling
No special requirements.
Any unused product and all materials that have been in contact with it should be disposed of in accordance with local requirements.

6.7. Marketing authorization holder
Pierre Fabre Medicament
45, Place Abel Gance
92100 Boulogne - FRANCE

6.8. Manufacturer
Pierre Fabre Medicament Production
45, Place Abel Gance
92100 Boulogne - FRANCE

Last revision: May 2014